ULTIMATE Study for Weight Loss

Obesity Clinical Trial

— ULTIMATE  

Official title:

Evaluating Impact of ULTIMATE Number of G-CATH EZ- Suture Anchors Placed Endoscopically on Motility, Metabolism, Satiety, and Weight Utilizing the Incisionless Operating Platform for the Treatment of Primary Obesity

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01771276
• Other study ID #: TPR602
• Status: Completed
• Phase: N/A
• First received: September 4, 2012
• Last updated: April 1, 2015
• Start date: June 2012
• Est. completion date: December 2013

Study information

• Verified date: April 2015
• Source: USGI Medical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to help find out more about how the Primary Obesity Surgery Endoluminal (POSE) procedure makes patients feel less hungry and fuller faster, leading to weight loss. In this study, USGI Medical wants to see if stomach emptying and gastro-intestinal hormone levels change after a POSE procedure with an increased (as compared to typical) number of anchors placed.

Description:

This study will use the USGI Medical Incisionless Operating Platform (IOP) to determine the affects of placing more Suture Anchors per patient (as compared to the current practice) in Primary Obesity Surgery Endoluminal(POSE). USGI wants to see if placing more anchors (particularly in the distal body/antrum region) significantly impacts primary weight loss, satiety, and metabolic outcomes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: December 2013
• Est. primary completion date: December 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 60 Years

Eligibility

Inclusion Criteria:

• Has a BMI of >30 and <40

• Male or female =21 yrs. of age and < 60 yrs. of age at time of enrollment

• Patient has had no significant weight change (+/- 5% of total body weight) in last 6 months but has been able to lose significant weight in the past with diet and exercise.

• Is a reasonable candidate for general anesthesia

• Agrees not to have any additional weight loss interventional procedures or liposuction for at least 18 months following study enrollment and agrees not to take any prescription or over the counter weight loss medications for at least 1 year.

• Physically and mentally able to comply with the visit schedule, ancillary testing, and behavior modification (diet and exercise) required for the study and agrees to study commitment requirements

• Had successful completion of the pre-screening, nutritional and educational programs and psychological assessment supporting that the subject is an appropriate bariatric surgical candidate

Exclusion Criteria:

• History of (or intra-operative evidence of) bariatric, gastric or esophageal surgery

• Esophageal stricture or other anatomy and/or condition that could preclude passage of endolumenal instruments

• Moderate to severe Gastro-esophageal reflux disease (GERD)

• Known hiatal hernia >3cm by history or as determined by UGI exam or endoscopy

• Known GI motility disorder or pancreatic insufficiency/disease

• Intra-operative Exclusion: Active peptic ulcer or hiatal hernia >3cm

• Pregnancy.

• Present Corticosteroid Use

• History of inflammatory disease of GI tract

• Severe coagulopathies, hepatic insufficiency or cirrhosis

• History or present use of insulin or insulin derivatives for treatment of diabetes

• Had Type II Diabetes Mellitus (as defined by HgbA1c >6.0) for greater than 2 years at the time of enrollment

• Uncontrolled Type II DM (HgbA1c >7.0 at screening)

• Patient has quit smoking within last 6 months at time of enrollment or plans to quit smoking in the next year

• Patient has a history of drug or alcohol abuse or actively abusing either

• Patient is presently being treated with medication for depression, psychosis, or other mood or eating disorder

• Non-ambulatory or has significant impairment of mobility

• Works for, or is first degree relative of investigator, study institution, or support staff involved in the study.

• Known hormonal or genetic cause for obesity

• Participating in another clinical study

• Patient is on medications known to impact GI motility or gut hormones that cannot be discontinued prior to nuclear testing

• Have work hours, family obligations or transportation issues that could interfere with patient returning for all scheduled evaluations, tests and nutritional counseling.

• Lives >60 kilometers from investigator site.

• Patient is not able to provide written informed consent

Related Conditions & MeSH terms

• Obesity

Intervention

Device:
• g-Cath Suture Anchor Delivery Catheter
Evaluate changes in emptying, hormones, satiety and weight loss with use of the g-Cath Suture Anchor Delivery Catheter in maximizing g-Cath Suture Anchor placement to as high as 25 anchors.

Locations

Country	Name	City	State
Spain	Centro Medico Teknon	Barcelona

Sponsors (1)

Lead Sponsor	Collaborator
USGI Medical

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Satiety	This test consists of determining if there is a Clinically significant change in Satiety pre and post POSE. The subjects ingest a nutritional drink (Ensure) at a constant rate of 30 mL per minute, constantly filling the glass with a perfusion pump (Gemini PC-2, IMED, San Diego, CA). (The subjects are not conscious of the volume being ingested.) The subjects are instructed to maintain consumption at the fill rate. Participants take note of their sensation of satiety with a graphical classification scale, which combines verbal descriptors on a scale of 0 to 5 (0 = no symptoms, 1 = first sensation of fullness [threshold]; 2 = light, 3 = moderate, 4 = severe, and 5 = maximum fullness or unbearable). The participants are told to stop taking the food product when a score of 5 is obtained. The maximum consumption of volume of the nutritional drink is recorded.	Immediately Pre-procedure, & 2 & 6 months post procedure
Other	Peptide Measurements	This test consists of determining if there is a Clinically significant change in peptides pre and post procedure.; Samples to be collected when fasting and 30, 60, 90, and 120 minutes after a standard meal (A meal consisting of 400 calories is used), The meal must be consumed within 10 minutes.; Samples to be collected by ELISA are: C-peptide, serum insulin, glucose, PYY, GLP-1 (active), leptin, and GIP. Total ghrelin level to be analyzed by RIA.	Immediately Pre-procedure & 2 Months post procedure
Primary	Weight Loss	Weight loss will be monitored and recorded on a monthly basis for up to 18 months post POSE with the proportion of subjects achieving =25% excess weight loss (EWL) at 12 months (Met Life criteria)being the primary efficacy endpoint	18 months
Secondary	Gastric emptying	This test consists of determining if there is a Clinically significant change in the duration of a radioactive marker (which is non-absorbable, and free of any food components) in a stomach pre and post POSE. In order to carry out this test, a piece of food is marked with a radioactive isotope and, by using an abdominal gamma camera; detections of radioactivity are made in the stomach during the postprandial period.	Immediately Pre-procedure, & 2 & 6 months post procedure